Clinical trial NCT00845975: Study of Low Level Laser Therapy and Tinnitus Relief
Official title: A Double-blind, Placebo-controlled Randomized Evaluation of the Application of Low Level Laser Light Therapy Using the Erchonia Hearing Lasers for the Relief of Tinnitus Clinical Study Protocol.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Tinnitus
Lead sponsor: Erchonia Corporation
Sponsor class: INDUSTRY
First posted: 2009-02-18
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if low level laser light therapy might help to relieve tinnitus in adults.

Detailed description: Tinnitus is the perception of sound, such as a ringing or hissing, that occurs in the ears or head in the absence of external stimuli. About 40-50 million people in the United States report experiencing tinnitus; 10-12 million have sought medical help for their tinnitus, with 2.5 million reporting their tinnitus as debilitating. As a result of the distressing nature of tinnitus, it is often accompanied by anxiety, depression and sleep difficulties.

Tinnitus is most often caused by sensorineural hearing loss due to presbyacusis (aging) or noise damage. It is believed that the tinnitus results when spurious neuro-electrical signals are produced by diseased, degenerated or damaged cochlear hair cells and interpreted by the brain as tinnitus.

There is presently no cure for tinnitus. Current management strategies include using other external sounds to distract from the tinnitus, teaching relaxation and stress reduction techniques, and prescription medications to help ease stress, anxiety, depression and sleep difficulties. However, in general, current tinnitus management techniques are only minimally effective. It is believed that low level laser light therapy may offer a simple, non-invasive means of relieving the symptoms of tinnitus. In theory, low level laser light penetrates targeted tissues to stimulate the mitochondria in underlying cells to produce energy through the production of adenosine triphosphate (ATP). In turn, the enhanced ATP fuels cellular energy and enhances blood flow to the cochlear hair cells (cilia) to assists in regulating the electrical signals disrupted by the diseased and/or degenerated cochlear hair cells. With the taming of the spurious electrical signals, the brain no longer has a basis to perceive the noise known as tinnitus.

Eligibility criteria: Inclusion Criteria:

* Total score on the Tinnitus Handicap Inventory (THI) of at least 20.
* Tinnitus is on-going; present for more than 50% of the time over the past 6 months.
* Subject has been previously evaluated by a qualified health care professional for tinnitus and received a diagnosis of etiology of tinnitus related to hearing impairment and/or noise exposure and/or unknown.
* Any existing hearing loss stable over the past 12 months.
* Willingness to abstain from partaking in other, non-study procedures indicated to lessen tinnitus and/or its perception, with the exclusion of wearing hearing aids for those subjects who enter the study using hearing aids, throughout the course of study participation.
* Willing and able to refrain from engaging in activities or work involving loud noise exposure, such as hunting, rock concerts and work situations that involve working around loud machinery, construction sites, etc., throughout the course of study participation.
* 18 years or older.
* Male or female.
* English as primary spoken language.

Exclusion Criteria:

* Presence of any of the following or in the subject's medical history:
* physical trauma or surgery to the head or neck
* uncontrolled hypertension
* current or prior surgically removed acoustic neuroma middle ear infection/active drainage from the ear and/or history of either within the previous 90 days
* impacted cerumen
* thyroid disease
* vascular disorders
* Temporomandibular Joint Disorder (TMJD)
* nutritional deficiency
* aneurysm
* multiple sclerosis
* Episodic or infrequent tinnitus
* Somatic or pulsatile tinnitus
* Prior history of sudden hearing loss and/or fluctuating hearing levels .
* Consistent use of any of the following drugs within the past 30 days:

NSAIDS; aspirin and other salicylates; Lasix and ther "loop"diuretics; "mycin" antibiotics such as vancomycin; quinine and related drugs; Chemotherapy agents such as cis-platin.

* Acute or chronic vertigo/dizziness.
* Prior diagnosis of central auditory processing disorder.
* Ménière's disease.
* Tympanic membrane perforation or tubes.
* Prior stapedectomy
* Prior mastoidectomy.
* Otosclerosis.
* Otosyphilis.
* Labyrinthitis.
* Auditory nerve damage.
* Stapedius myoclonus syndrome.
* Brain and/or brainstem injury.
* Cochlear implant.
* Photosensitivity disorder.
* Active/open infection, wound or other external trauma to the areas to be treated with the Hearing Laser.
* Pregnant or lactating.
* Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years.
* Developmental disability or cognitive impairment that would make it difficult for the subject to partake in the clinical study, including adequate comprehension of the informed consent form and ability to record the necessary measurements.
* History of drug or alcohol abuse.
* Involvement in litigation and/or a worker's compensation claim and/or receiving disability benefits related to tinnitus and/or hearing loss.
* Participation in research in the past 30 days.

Primary outcomes:
measure: Total Score on the Tinnitus Handicap Inventory (THI).
timeFrame: baseline and one week
Secondary outcomes:
measure: Beck Depression Inventory-II (BDI-II)
timeFrame: baseline and 4 weeks
measure: Spielberger State-Trait Anxiety Inventory (STAI)- Trait Portion
timeFrame: baseline and 4 weeks
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: McDonald Hearing Aid Center
state: California
Study officials:
affiliation: McDonald Hearing Aid Centers
name: Louis A Looper, MA, CCC-A
role: PRINCIPAL_INVESTIGATOR
References: